<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/app/plugins/xml-sitemap-feed/assets/sitemap-news.xsl?ver=5.7.7"?>
<!-- generated-on="2026-07-17T17:38:00+00:00" -->
<!-- generator="XML Sitemap & Google News for WordPress" -->
<!-- generator-url="https://status301.net/wordpress-plugins/xml-sitemap-feed/" -->
<!-- generator-version="5.7.7" -->
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" >
<url><loc>https://www.pharma-marketing.com/novartis-klinikum-bayreuth-and-myon-clinic-launch-digital-rlt-network/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-17T12:01:57+00:00</news:publication_date><news:title>Novartis, Klinikum Bayreuth and myon.clinic launch digital RLT network</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/de/novartis-klinikum-bayreuth-und-myon-clinic-starten-digitales-rlt-netzwerk/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>de</news:language></news:publication><news:publication_date>2026-07-17T12:01:57+00:00</news:publication_date><news:title>Novartis, Klinikum Bayreuth und myon.clinic starten digitales RLT-Netzwerk</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/schwabe-takes-majority-stake-in-hydraid/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-17T11:26:58+00:00</news:publication_date><news:title>Schwabe takes majority stake in Hydraid</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/de/schwabe-uebernimmt-mehrheit-an-hydraid/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>de</news:language></news:publication><news:publication_date>2026-07-17T11:26:57+00:00</news:publication_date><news:title>Schwabe übernimmt Mehrheit an Hydraid</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/comprix-advisory-board-appoints-christoph-bohlender/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-17T10:57:51+00:00</news:publication_date><news:title>COMPRIX advisory board appoints Christoph Bohlender</news:title></news:news></url>
<url><loc>https://www.pharma-marketing.com/de/comprix-beirat-christoph-bohlender-rueckt-ins-gremium/</loc><news:news><news:publication><news:name>Pharma-Marketing.com</news:name><news:language>de</news:language></news:publication><news:publication_date>2026-07-17T10:57:50+00:00</news:publication_date><news:title>COMPRIX-Beirat: Christoph Bohlender rückt ins Gremium</news:title></news:news></url>
</urlset>
